在爱泼斯坦-巴尔病毒潜伏膜蛋白2中鉴定出一种不依赖抗原加工相关转运体（TAP）、依赖免疫蛋白酶体的CD8 + T细胞表位。
Identification of a TAP-independent, immunoproteasome-dependent CD8+ T-cell epitope in Epstein-Barr virus latent membrane protein 2.
作者信息
Lautscham Georg, Haigh Tracey, Mayrhofer Sabine, Taylor Graham, Croom-Carter Debbie, Leese Alison, Gadola Stephan, Cerundolo Vincenzo, Rickinson Alan, Blake Neil
机构信息
Cancer Research UK Institute for Cancer Studies, University of Birmingham, Birmingham, UK.
出版信息
J Virol. 2003 Feb;77(4):2757-61. doi: 10.1128/jvi.77.4.2757-2761.2003.
Abstract
We have identified an HLA-A2-restricted CD8(+) T-cell epitope, FLYALALLL, in the Epstein-Barr virus (EBV) latent membrane protein 2 (LMP2), an important target antigen in the context of EBV-associated malignancies. This epitope is TAP independent, like other hydrophobic LMP2-derived epitopes, but uniquely is dependent upon the immunoproteasome for its generation.
摘要
我们在爱泼斯坦-巴尔病毒（EBV）潜伏膜蛋白2（LMP2）中鉴定出一个HLA-A2限制性CD8(+) T细胞表位FLYALALLL，LMP2是EBV相关恶性肿瘤中的一个重要靶抗原。与其他源自LMP2的疏水表位一样，该表位不依赖抗原加工相关转运体（TAP），但其产生独特地依赖免疫蛋白酶体。
相似文献
1
Identification of a TAP-independent, immunoproteasome-dependent CD8+ T-cell epitope in Epstein-Barr virus latent membrane protein 2.在爱泼斯坦-巴尔病毒潜伏膜蛋白2中鉴定出一种不依赖抗原加工相关转运体（TAP）、依赖免疫蛋白酶体的CD8 + T细胞表位。
J Virol. 2003 Feb;77(4):2757-61. doi: 10.1128/jvi.77.4.2757-2761.2003.
2
Processing of a multiple membrane spanning Epstein-Barr virus protein for CD8(+) T cell recognition reveals a proteasome-dependent, transporter associated with antigen processing-independent pathway.一种跨膜多次的爱泼斯坦-巴尔病毒蛋白用于CD8(+) T细胞识别的加工过程揭示了一条蛋白酶体依赖性、与抗原加工无关的转运体相关途径。
J Exp Med. 2001 Oct 15;194(8):1053-68. doi: 10.1084/jem.194.8.1053.
3
Transporter (TAP)-independent processing of a multiple membrane-spanning protein, the Epstein-Barr virus latent membrane protein 2.转运体（TAP）非依赖性加工一种多跨膜蛋白，即爱泼斯坦-巴尔病毒潜伏膜蛋白2 。
Eur J Immunol. 1996 Aug;26(8):1875-83. doi: 10.1002/eji.1830260831.
4
Three immunoproteasome-associated subunits cooperatively generate a cytotoxic T-lymphocyte epitope of Epstein-Barr virus LMP2A by overcoming specific structures resistant to epitope liberation.三种免疫蛋白酶体相关亚基通过克服对表位释放具有抗性的特定结构，协同产生爱泼斯坦-巴尔病毒LMP2A的细胞毒性T淋巴细胞表位。
J Virol. 2006 Jan;80(2):883-90. doi: 10.1128/JVI.80.2.883-890.2006.
5
Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane protein 2A: implications for cytotoxic T-lymphocyte control of EBV-associated malignancies.肽转运体（TAP-1和TAP-2）非依赖性的爱泼斯坦-巴尔病毒（EBV）潜伏膜蛋白2A的内源性加工：对EBV相关恶性肿瘤细胞毒性T淋巴细胞控制的影响
J Virol. 1996 Aug;70(8):5357-62. doi: 10.1128/JVI.70.8.5357-5362.1996.
6
Sustained CD8+ T-cell immune response to a novel immunodominant HLA-B*0702-associated epitope derived from an Epstein-Barr virus helicase-primase-associated protein.对源自爱泼斯坦-巴尔病毒解旋酶-引发酶相关蛋白的一种新的免疫显性HLA-B*0702相关表位产生持续的CD8+ T细胞免疫反应。
J Med Virol. 2004 Apr;72(4):635-45. doi: 10.1002/jmv.20023.
7
Phenotypic and functional heterogeneity of EBV epitope-specific CD8+ T cells.EBV表位特异性CD8+ T细胞的表型和功能异质性
J Immunol. 2002 Apr 15;168(8):4184-91. doi: 10.4049/jimmunol.168.8.4184.
8
Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.爱泼斯坦-巴尔病毒潜伏膜蛋白1恢复伯基特淋巴瘤细胞内源性抗原加工：肽转运体和HLA-I类抗原表达的协同上调
Eur J Immunol. 1995 May;25(5):1374-84. doi: 10.1002/eji.1830250536.
9
10
Epstein-Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products.爱泼斯坦-巴尔病毒通过多种基因产物的协同作用逃避CD8(+)和CD4(+) T细胞免疫。
Semin Cancer Biol. 2008 Dec;18(6):397-408. doi: 10.1016/j.semcancer.2008.10.008. Epub 2008 Oct 25.
引用本文的文献
1
Immunoproteasome acted as immunotherapy 'coffee companion' in advanced carcinoma therapy.免疫蛋白酶体在晚期癌症治疗中充当免疫疗法的“咖啡伴侣”。
Front Immunol. 2024 Aug 30;15:1464267. doi: 10.3389/fimmu.2024.1464267. eCollection 2024.
2
Incongruity between T cell receptor recognition of breast cancer hotspot mutations ESR1 Y537S and D538G following exogenous peptide loading versus endogenous antigen processing.外源性肽加载与内源性抗原加工后，T 细胞受体识别乳腺癌热点突变 ESR1 Y537S 和 D538G 存在不一致性。
Cytotherapy. 2024 Mar;26(3):266-275. doi: 10.1016/j.jcyt.2023.12.002. Epub 2024 Jan 15.
3
AIM™ platform: A new immunotherapy approach for viral diseases.AIM™平台：一种针对病毒性疾病的新型免疫疗法。
Front Med (Lausanne). 2022 Dec 23;9:1070529. doi: 10.3389/fmed.2022.1070529. eCollection 2022.
4
Epstein-Barr virus microRNAs reduce immune surveillance by virus-specific CD8+ T cells.爱泼斯坦-巴尔病毒微小RNA通过病毒特异性CD8 + T细胞降低免疫监视。
Proc Natl Acad Sci U S A. 2016 Oct 18;113(42):E6467-E6475. doi: 10.1073/pnas.1605884113. Epub 2016 Oct 3.
5
Immunodominant West Nile Virus T Cell Epitopes Are Fewer in Number and Fashionably Late.免疫显性西尼罗河病毒T细胞表位数量较少且出现较晚。
J Immunol. 2016 May 15;196(10):4263-73. doi: 10.4049/jimmunol.1501821. Epub 2016 Apr 20.
6
A Safeguard System for Induced Pluripotent Stem Cell-Derived Rejuvenated T Cell Therapy.诱导多能干细胞衍生的 rejuvenated T 细胞治疗的防护系统。
Stem Cell Reports. 2015 Oct 13;5(4):597-608. doi: 10.1016/j.stemcr.2015.07.011. Epub 2015 Aug 28.
7
Latent Membrane Protein LMP2A Impairs Recognition of EBV-Infected Cells by CD8+ T Cells.潜伏膜蛋白LMP2A损害CD8 + T细胞对EBV感染细胞的识别。
PLoS Pathog. 2015 Jun 11;11(6):e1004906. doi: 10.1371/journal.ppat.1004906. eCollection 2015 Jun.
8
Chimerically fused antigen rich of overlapped epitopes from latent membrane protein 2 (LMP2) of Epstein-Barr virus as a potential vaccine and diagnostic agent.源自爱泼斯坦-巴尔病毒潜伏膜蛋白2（LMP2）的富含重叠表位的嵌合融合抗原，作为一种潜在的疫苗和诊断试剂。
Cell Mol Immunol. 2016 Jul;13(4):492-501. doi: 10.1038/cmi.2015.29. Epub 2015 Apr 13.
9
Novel mechanisms of EBV-induced oncogenesis.EBV 诱导致癌的新机制。
Curr Opin Virol. 2012 Aug;2(4):453-8. doi: 10.1016/j.coviro.2012.07.001. Epub 2012 Aug 1.
10
Cross-presentation of IgG-containing immune complexes.IgG 免疫复合物的交叉呈递。
Cell Mol Life Sci. 2013 Apr;70(8):1319-34. doi: 10.1007/s00018-012-1100-8. Epub 2012 Jul 31.
本文引用的文献
1
The role of the proteasome activator PA28 in MHC class I antigen processing.蛋白酶体激活剂PA28在MHC I类抗原加工中的作用。
Mol Immunol. 2002 Oct;39(3-4):165-9. doi: 10.1016/s0161-5890(02)00099-8.
2
Processing of a multiple membrane spanning Epstein-Barr virus protein for CD8(+) T cell recognition reveals a proteasome-dependent, transporter associated with antigen processing-independent pathway.一种跨膜多次的爱泼斯坦-巴尔病毒蛋白用于CD8(+) T细胞识别的加工过程揭示了一条蛋白酶体依赖性、与抗原加工无关的转运体相关途径。
J Exp Med. 2001 Oct 15;194(8):1053-68. doi: 10.1084/jem.194.8.1053.
3
4
The 26S proteasome: a molecular machine designed for controlled proteolysis.26S蛋白酶体：一种专为可控蛋白水解而设计的分子机器。
Annu Rev Biochem. 1999;68:1015-68. doi: 10.1146/annurev.biochem.68.1.1015.
5
MHC class I antigen processing of an adenovirus CTL epitope is linked to the levels of immunoproteasomes in infected cells.腺病毒细胞毒性T淋巴细胞表位的MHC I类抗原加工与感染细胞中免疫蛋白酶体的水平相关。
J Immunol. 2000 May 1;164(9):4500-6. doi: 10.4049/jimmunol.164.9.4500.
6
Efficient generation of a hepatitis B virus cytotoxic T lymphocyte epitope requires the structural features of immunoproteasomes.高效生成乙型肝炎病毒细胞毒性T淋巴细胞表位需要免疫蛋白酶体的结构特征。
J Exp Med. 2000 Feb 7;191(3):503-14. doi: 10.1084/jem.191.3.503.
7
8
Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity.环氧莫司汀是一种强效且具选择性的蛋白酶体抑制剂，具有体内抗炎活性。
Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10403-8. doi: 10.1073/pnas.96.18.10403.
9
10
Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes.爱泼斯坦-巴尔病毒（EBV）致癌基因潜伏膜蛋白1（LMP1）内细胞毒性T细胞表位的鉴定：LMP1特异性细胞毒性T淋巴细胞对EBV感染细胞进行HLA A2超型限制免疫识别的证据
Eur J Immunol. 1998 Feb;28(2):451-8. doi: 10.1002/(SICI)1521-4141(199802)28:02<451::AID-IMMU451>3.0.CO;2-U.
Zotero 插件